Why the study?
Does clinical pharmacist participation reduce drug-related problems and costs in the intensive care unit?
Does clinical pharmacist participation reduce drug-related problems and costs in the intensive care unit?
Clinical pharmacist participation in ICU rounds is highly accepted by healthcare teams and has the potential to decrease drug-related costs.
Answers are grounded in this paper and cite their sources.
Supports pharmacist participation in ICU rounds; leaves open cost savings confirmation in randomized trials.
The CP's recommendations were highly accepted by the healthcare team. With the CP's participation in routine patient rounds in the healthcare team of the ICU, drug-related costs would also decrease.
No takes yet. Share an insight, caveat, or question.
Ayhan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: